Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Legend Biotech Corporation - American Depositary Shares (NQ:LEGN)

21.62 +0.36 (+1.69%)
Streaming Delayed Price Updated: 9:32 AM EDT, Aug 21, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Legend Biotech Corporation - American Depositary Shares

< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
News headline image
The Daily Biotech Pulse: Setback For NRx Pharma's COVID Study, Fast Track Tag For Pfizer's NASH Combo Therapy, Reata's Ataxia Drug In FDA Review ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
CARVYKTI® (ciltacabtagene autoleucel) Granted Conditional Approval by the European Commission for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
From Legend Biotech
Via Business Wire
News headline image
Legend Biotech to Highlight Continued Progress in the Treatment of Multiple Myeloma With Updated Data From BCMA CAR-T Studies at 2022 ASCO and EHA
From Legend Biotech
Via Business Wire
News headline image
Legend Biotech Appoints Lori Macomber as Chief Financial Officer
From Legend Biotech
Via Business Wire
News headline image
Legend Biotech Announces Participation in Upcoming Investor Conferences
From Legend Biotech
Via Business Wire
News headline image
Legend Biotech Announces Appointment of Global Head of Research and Early Development
From Legend Biotech Corporation
Via Business Wire
News headline image
Most Chinese Biotech Stocks Can Continue US Listing After New Audit Framework ↗
 
Via Benzinga
News headline image
HFCAA News: 128 Chinese Stocks the SEC Could Delist ↗
The SEC has released a massive list of Chinese stocks that could face delisting on Holding Foreign Companies Accountable Act news. 
Via InvestorPlace
News headline image
EMA's CHMP Clears Janssen, Legend's Multiple Myeloma CAR-T Therapy ↗
The European Medicines Agency's CHMP  
Via Benzinga
News headline image
CARVYKTI® (ciltacabtagene autoleucel) Receives Positive CHMP Opinion for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
From Legend Biotech
Via Business Wire
News headline image
Flanders Investment and Trade Names Legend Biotech Newcomer of the Year
From Legend Biotech
Via Business Wire
News headline image
Legend Biotech Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Highlights
From Legend Biotech
Via Business Wire
News headline image
Analyst Ratings For Legend Biotech ↗
Analysts have provided the following ratings for Legend Biotech (NASDAQ:LEGN) within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total... 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For March 15, 2022 ↗
Upgrades For Turquoise Hill Resources Ltd (NYSE:TRQ), BMO Capital upgraded the previous rating of Underperform to Market Perform. Turquoise Hill Resources earned $0.78 in the... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
Gainers Erytech Pharma (NASDAQ:ERYP) stock rose 18.7% to $1.65 during Monday's pre-market session. The market value of their outstanding shares is at $51.1 million.... 
Via Benzinga
News headline image
The Week Ahead In Biotech (March 6-12): Quiet Week On Tap With Earnings Season Reaching It Final Leg ↗
Biotech stocks reversed course in the week ending March 4, as the Ukrainian crisis weighed down on the broader market as well as the sector. The iShares Biotechnology ETF (... 
Via Benzinga
News headline image
Week In Review: Adagene Forms $2.5 Billion, Four-Drug Partnership With Sanofi ↗
Adagene will apply its technology to as many as four Sanofi candidates in a collaboration worth up to $2.5 billion. Huadong Medicine will acquire Asia rights for two Heidelberg Pharma ADC candidates in... 
Via Talk Markets
News headline image
GenScript Losses Widen, But Investors Focus on Newly Approved Cancer Treatment ↗
Key takeaways: GenScript Biotech said it lost up to $519 million last year, with its Legend Biotech unit accounting for nearly 70% of that Legend Biotech’s Cilta-cel CAR-T... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Legend Biotech, CTI Biopharma Receive FDA Approvals, AbbVie Announces Delay In Skyrizi Review, Editas Gains On CRISPR Patent Resolution ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Editas Gains On Resolution Of CRISPR Gene Editing Patent Case Editas Medicine... 
Via Benzinga
News headline image
FDA Approves JNJ-Legend Biotech Partnered Blood Cancer Therapy ↗
The FDA has approved Legend Biotech Corporation's (NASDAQ: LEGN) first product, Carvykti (ciltacabtagene autoleucel; cilta-cel), for relapsed or refractory... 
Via Benzinga
News headline image
The Week Ahead In Biotech (Feb. 27-March 5): Earnings, Multiple Regulatory Decisions Take The Spotlight ↗
Biopharma stocks lock-stepped with the broader market in the week ending Feb. 25 before finishing higher. The trajectory was the same, with the sector declining in the first two sessions of the... 
Via Talk Markets
News headline image
The Week Ahead In Biotech (Feb. 27-March 5): Earnings, Multiple Regulatory Decisions Take The Spotlight ↗
Biopharma stocks lock-stepped with the broader market in the week ending Feb. 25 before finishing higher. The trajectory was the same, with the sector declining in the first... 
Via Benzinga
News headline image
Week In Review: AffaMed Announced US Approval To Start Clinical Trials ↗
AffaMed recently in-licensed ex-Asia (plus Japan) rights to a novel bispecific biologic molecule aimed at retinal vascular diseases from AskGene Pharma. On Saturday, AffaMed announced US approval to... 
Via Talk Markets
News headline image
Legend Biotech Announces Preliminary Results for the Year Ended December 31, 2021
From Legend Biotech
Via Business Wire
News headline image
FDA Slams Brakes On Legend Biotech's CAR-T Therapy Trial In Lymphoma Patients ↗
The FDA has instituted a clinical hold on Legend Biotech Corporation's (NASDAQ: LEGN) Phase 1 trial for LB1901. LB1901 is the company's... 
Via Benzinga
News headline image
Legend Biotech Announces FDA Clinical Hold of its Phase 1 Clinical Trial for LB1901
From Legend Biotech
Via Business Wire
News headline image
Legend Biotech Achieves Milestone Payments in BCMA CAR-T Collaboration with Janssen
From Legend Biotech
Via Business Wire
News headline image
Attention Biotech Investors: Mark Your Calendar For These Key February PDUFA Dates ↗
After a fairly robust 2021, the new year started on a mixed note as far as regulatory decisions are concerned. 
Via Benzinga
News headline image
Legend Biotech to Participate in the 40th Annual J.P. Morgan Healthcare Conference
From Legend Biotech Corporation
Via Business Wire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For January 31, 2022 ↗
Upgrades UBS upgraded the previous rating for Align Technology Inc (NASDAQ:ALGN) from Neutral to Buy. For the third quarter, Align Tech had an EPS of $2.87, compared to year-ago... 
Via Benzinga
< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.